• 1
    Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003; 361: 22352242.
  • 2
    Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994; 54: 14311439.
  • 3
    Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997; 8: 837855.
  • 4
    Wall ME, Wani MC, Cooke CE, Palmer KH, Mcphail AT. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88: 38883890.
  • 5
    Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972; 56: 515521.
  • 6
    Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 2001; 41: 5377.
  • 7
    Sordet O, Khan QA, Kohn KW, Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr Med Chem Anti-Canc Agents 2003; 3: 271290.
  • 8
    Kohn KW, Shao RG, Pommier Y. How do drug-induced topoisomerase I-DNA lesions signal to the molecular interaction network that regulates cell cycle checkpoints, DNA replication, and DNA repair? Cell Biochem Biophys 2000; 33: 175180.
  • 9
    Chatterjee D, Schmitz I, Krueger A, Yeung K, Kirchhoff S, Krammer PH, et al. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short). Cancer Res 2001; 61: 71487154.
  • 10
    LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8: 274281.
  • 11
    Suzuki A, Iwasaki M, Kato M, Wagai N. Sequential operation of ceramide synthesis and ICE cascade in CPT-11-initiated apoptotic death signaling. Exp Cell Res 1997; 233: 4147.
  • 12
    Shimizu T, Pommier Y. DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies. Exp Cell Res 1996; 226: 292301.
  • 13
    Vasey PA, Jones NA, Jenkins S, Dive C, Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmakol 1996; 50: 15361540.
  • 14
    Park DS, Morris EJ, Greene LA, Geller, H.M. G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis. J Neuroscience 1997; 17: 12561270.
  • 15
    Shimizu T, Pommier Y. Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases. Leukemia 1997; 11: 12381244.
  • 16
    Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW, et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 1996; 56: 44304437.
  • 17
    Morris EJ, Geller HM. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J Cell Biol 1996; 134: 757770.
  • 18
    Seimiya H, Mashima T, Toho M, Tsuruo T. c-Jun NH2-terminal kinase-mediated activation of interleukin-1 beta-converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J Biol Chem 1997; 272: 46314636.
  • 19
    Keppler D, Lesch R, Reutter W, Decker K. Experimental hepatitis induced by D-galactosamine. Exp Mol Pathol 1968; 9: 279290.
  • 20
    Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci U S A 1979; 76: 59395943.
  • 21
    Wieland T. Poisonous principles of mushrooms of the genus Amanita. Four-carbon amines acting on the central nervous system and cell-destroying cyclic peptides are produced. Science 1968; 159: 946952.
  • 22
    Bader M, Thrum H, Guttner J, Klinger W. Actinomycin D: toxicity, liver functions and morphological findings in rats. Acta Biol Med Ger 1974; 32: 9198.
  • 23
    Leist M, Gantner F, Bohlinger I, Germann PG, Tiegs G, Wendel A. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J Immunol 1994; 153: 17781787.
  • 24
    Leist M, Gantner F, Künstle G, Wendel A. Cytokine-mediated hepatic apoptosis. Rev Physiol Biochem Pharmacol 1998; 133: 109155.
  • 25
    Bendixen C, Thomsen B, Alsner J, Westergaard O. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry 1990; 29: 56135619.
  • 26
    Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997; 15: 20902096.
  • 27
    Ohtsu T, Sasaki Y, Igarashi T, Murayama T, Kobayashi Y, Tobinai K. Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide. Jpn J Clin Oncol 1998; 28: 502506.
  • 28
    Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993; 364: 798802.
  • 29
    Bergmeyer HU. Methods of Enzymatic Analysis. Vol 3. Weinheim: Verlag Chemie; 1983.
  • 30
    Seglen PO. Preparation of rat liver cells: enzymatic requirements for tissue dispersion. Exp Cell Res 1991; 2: 391398.
  • 31
    Latta M, Künstle G, Leist M, Wendel A. Metabolic depletion of ATP by fructose inversely controls CD95- and tumor necrosis factor receptor 1-mediated hepatic apoptosis. J Exp Med 2000; 191: 19751986.
  • 32
    Pierce RH, Campbell JS, Stephenson AB, Franklin CC, Chaisson M, Poot M, et al. Disruption of redox homeostasis in tumor necrosis factor-induced apoptosis in a murine hepatocyte cell line. Am J Pathol 2000; 157: 221236.
  • 33
    Wu JC, Merlino G, Fausto N. Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci U S A 1994; 91: 674678.
  • 34
    Leist M, Gantner F, Künstle G, Bohlinger I, Tiegs G, Bluethmann H, et al. The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure. Mol Med 1996; 2: 109124.
  • 35
    Schotte P, Declercq W, Van Huffel S, Vandenabeele P, Beyaert R. Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett 1999; 442: 117121.
  • 36
    Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998; 273: 3260832613.
  • 37
    Rodriguez I, Matsuura K, Ody C, Nagata S, Vassalli P. Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J Exp Med 1996; 184: 20672072.
  • 38
    Künstle G, Leist M, Uhlig S, Revesz L, Feifel R, MacKenzie A, et al. ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-alpha. Immunol Lett 1997; 55: 510.
  • 39
    Baloch Z, Cohen S, Coffman FD. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II. J Immunol 1990; 145: 29082913.
  • 40
    Utsugi T, Mattern MR, Mirabelli CK, Hanna N. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res 1990; 50: 26362640.
  • 41
    Kyprianou N, Alexander RB, Isaacs JT. Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells. J Natl Cancer Inst 1991; 83: 346350.
  • 42
    Orengo G, Noviello E, Cimoli G, Pagnan G, Parodi S, Venturini M, et al. Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation. Jpn J Cancer Res 1992; 83: 11321136.
  • 43
    Dejosez M, Ramp U, Mahotka C, Krieg A, Walczak H, Gabbert HE, et al. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ 2000; 7: 11271136.
  • 44
    Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000; 20: 205212.
  • 45
    Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 4565.
  • 46
    Valente P, Arzani D, Cesario A, Margaritora S, Carbone E, Russo P. TNF increases camptothecin-induced apoptosis by inhibition of NF-kappa B. Eur J Cancer 2003; 39: 14681477.
  • 47
    Gomez-Lechon MJ, O'Connor E, Castell JV, Jover R. Sensitive markers used to identify compounds that trigger apoptosis in cultured hepatocytes. Toxicol Sci 2002; 65: 299308.
  • 48
    Siendones E, Fouad D, Mohamed Kamal El Said Abou-Elella A, Quintero A, Barrera P, Muntane J. Role of nitric oxide in D-galactosamine-induced cell death and its protection by PGE(1) in cultured hepatocytes. Nitric Oxide 2003; 8: 133143.
  • 49
    Osypiw JC, Allen RL, Billington D. Subpopulations of rat hepatocytes separated by Percoll density-gradient centrifugation show characteristics consistent with different acinar locations. Biochem J 1994; 304: 617624.
  • 50
    Goto S, Okutomi T, Suma Y, Kera J, Soma G, Takeuchi S. Induction of tumor necrosis factor by a camptothecin derivative, irinotecan, in mice and human mononuclear cells. Anticancer Res 1996; 16: 25072511.